GH Secretagogue Comparison · 2026
Tesamorelin vs. CJC-1295 + Ipamorelin: Visceral Fat, IGF-1 & GH Pulsatility
Executive Brief
Tesamorelin and the CJC-1295 + Ipamorelin combination are the two dominant growth hormone secretagogue (GHS) regimens in metabolic and body-composition research. Tesamorelin is a full-length 44-amino-acid GHRH analog backed by FDA approval (as Egrifta) and Phase 3 RCTs demonstrating 15%–20% selective visceral adipose tissue (VAT) reduction. CJC-1295 (Mod GRF 1-29) + Ipamorelin pairs a 29-AA GHRH analog with a selective ghrelin/GHS-R1a pentapeptide for dual-receptor pituitary amplification, deep slow-wave sleep, and recovery.
Full-Length GHRH(1–44) vs. Dual GHRH-R + GHS-R1a
Tesamorelin vs. CJC-1295 + Ipamorelin: At-a-Glance Comparison (2026)
Unlike exogenous recombinant human growth hormone (somatropin)—which replaces endogenous GH with a flat, supraphysiological wave that shuts down pituitary somatotrophs and impairs insulin sensitivity—both Tesamorelin and CJC-1295 + Ipamorelin stimulate the anterior pituitary to release endogenous GH in physiological pulses subject to negative IGF-1 feedback.
| Clinical & Biochemical Parameter | Tesamorelin (TH9507 / Egrifta) | CJC-1295 (Mod GRF 1-29) + Ipamorelin |
|---|---|---|
| Molecular Structure | Full 44-AA human GHRH sequence with N-terminal trans-3-hexenoic acid (~5,135.9 Da) | Tetrasubstituted 29-AA GHRH fragment (~3,367.9 Da) + 5-AA pentapeptide Ipamorelin (~711.9 Da) |
| Pituitary Receptor Targets | Single Receptor: GHRH Receptor (GHRH-R) via cAMP/PKA | Dual Receptor: GHRH-R (cAMP/PKA) + Ghrelin GHS-R1a (PLC/IP3/Ca²⁺ & somatostatin blockade) |
| Elimination Half-Life | ~26–38 minutes (triggers natural multi-hour pulsatile GH release) | Mod GRF 1-29: ~30 min (or 6–8 days with DAC); Ipamorelin: ~2 hours |
| Visceral Fat (VAT) Clinical Data | −15.2% at 26 wks & −18% to −20% at 52 wks (NEJM Phase 3 RCTs, Falutz et al.) | Modest overall lipolysis & body-recomposition support; no Phase 3 CT-quantified VAT RCTs |
| Hepatic Fat (MASLD) Reduction | −37% relative liver fat reduction & blocked fibrosis progression (Lancet HIV, Fourman et al.) | Indirect hepatic lipid improvement via IGF-1/GH axis; no dedicated liver biopsy RCTs |
| Serum IGF-1 Elevation | +80% to +110% mean increase (~100–150 ng/mL above baseline at 1.4–2 mg/day) | +40% to +75% steady physiological elevation at 100–300 mcg/day each |
| Cortisol / Prolactin / Ghrelin Hunger | Zero direct ghrelin hunger; preserves physiological GH trough and nocturnal rhythm | Ipamorelin has near-zero cortisol/prolactin spillover (unlike GHRP-6/GHRP-2 or MK-677) |
| Standard Research Protocol | 1.0 mg to 2.0 mg SubQ once daily (fasted pre-bed, often 5 days on / 2 days off) | 100–200 mcg Mod GRF 1-29 + 100–200 mcg Ipamorelin SubQ 1–2x daily (fasted, 5 on / 2 off) |
| 2026 Regulatory Status | FDA-Approved (Egrifta SV / Egrifta WR) | Investigational / FDA 503A Category 2 list (not FDA-approved for commercial marketing) |
Peptide Engineering: Full-Length GHRH(1–44) vs. Tetrasubstituted GRF(1–29) + GHS-R1a
Native human Growth Hormone-Releasing Hormone (GHRH) is a 44-amino-acid hypothalamic peptide that travels down the hypophyseal portal system to stimulate somatotroph cells in the anterior pituitary. However, native GHRH is cleaved at its N-terminal Tyr1-Ala2 bond within 5 to 7 minutes in human plasma by the enzyme dipeptidyl peptidase-4 (DPP-4), rendering unmodified GHRH impractical as a therapeutic.
How Tesamorelin Solves DPP-4 Degradation: Developed by Theratechnologies and approved by the FDA in 2010 as Egrifta, tesamorelin (TH9507) retains the entire 44-amino-acid sequence of human GHRH—including the C-terminal residues 30–44 that stabilize receptor binding conformation—and attaches a hydrophobic trans-3-hexenoyl moiety to the N-terminal tyrosine residue. This hexenoic acid cap shields the peptide from DPP-4 enzymatic cleavage, extending its plasma half-life to 26–38 minutes and dramatically increasing its resistance to serum inactivation while preserving 100% natural GHRH receptor specificity.
How CJC-1295 (Mod GRF 1-29) + Ipamorelin Works: Early structure-activity studies showed that the first 29 amino acids of GHRH—known as sermorelin or GRF(1–29)—contain the core biologically active domain. By substituting four vulnerable amino acids at positions 2, 8, 15, and 27 (`D-Ala2, Gln8, Ala15, Leu27`), chemists created Modified GRF(1–29), commonly referred to as CJC-1295 without DAC, which has a ~30-minute half-life designed for clean pulsatile signaling (whereas CJC-1295 with DAC attaches a Drug Affinity Complex that binds serum albumin for a 6-to-8-day half-life, causing continuous basal GH bleed rather than natural pulses).
In the CJC-1295 + Ipamorelin stack, Mod GRF(1–29) is paired with ipamorelin (`Aib-His-D-2-Nal-D-Phe-Lys-NH2`), a selective pentapeptide agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a).
Receptor Physiology: Why Dual GHRH-R + GHS-R1a Differs From High-Potency GHRH-R Alone
Pituitary somatotrophs are regulated by a push-pull braking system: GHRH is the accelerator, while hypothalamic somatostatin (SRIF) is the brake.
- Tesamorelin's Full-Length GHRH-R Dominance: Because tesamorelin preserves the full 44-AA sequence with an N-terminal lipid modification, it binds GHRH-R with higher affinity and stability than truncated 29-AA fragments. In overnight 12-hour frequent-sampling deconvolution studies (Stanley et al., JCEM), tesamorelin increased both basal and pulsatile GH secretion amplitude without altering pulse frequency or disrupting the natural circadian nocturnal rhythm, driving robust hepatic IGF-1 increases of 80% to 110%.
- CJC-1295 + Ipamorelin's Synergistic Dual-Pathway Release: If a truncated GHRH analog like Mod GRF(1–29) is injected when hypothalamic somatostatin tone happens to be high, the resulting GH pulse is blunted. Adding ipamorelin activates the separate GHS-R1a receptor (via phospholipase C / IP3 / intracellular Ca²⁺ depolarization) and functionally antagonizes somatostatin inhibition at both the hypothalamus and pituitary. Consequently, co-administering 100 mcg of Mod GRF(1–29) with 100 mcg of ipamorelin produces a synergistic GH pulse significantly larger than the sum of either peptide administered alone.
- Endocrine Selectivity (ACTH, Cortisol & Prolactin): Earlier ghrelin mimetics like GHRP-2, GHRP-6, and hexarelin caused off-target spikes in adrenocorticotropic hormone (ACTH), cortisol, aldosterone, and prolactin. In landmark human selectivity studies (Raun et al., 1998), ipamorelin stimulated GH release with zero elevation in cortisol or prolactin even at doses more than 200-fold above its ED50—matching tesamorelin's clean pituitary selectivity.
Selective Visceral Adipose Lipolysis
Clinical Endpoints: Selective Visceral Fat (VAT) & Liver Fat vs. Sleep & Recovery
Where tesamorelin stands completely apart from every other growth hormone secretagogue is the depth of its randomized, double-blind, placebo-controlled Phase 3 human clinical trial evidence for selective visceral adipose tissue (VAT) clearance:
- 15% to 20% Visceral Fat Reduction Without Subcutaneous Fat Loss: Across two pivotal Phase 3 trials published in the New England Journal of Medicine and JAMA (Falutz et al., 2007 & 2010; n > 800), tesamorelin 2 mg daily reduced CT-measured visceral adipose tissue cross-sectional area by −15.2% at 26 weeks and −18% to −20% at 52 weeks (~31–35 cm² reduction), while completely preserving subcutaneous adipose tissue (SAT) and increasing lean skeletal muscle mass by ~1.3–1.5 kg. Visceral adipocytes surrounding abdominal organs express higher densities of beta-adrenergic and GH receptors than subcutaneous fat, making VAT uniquely responsive to high-amplitude pulsatile GH lipolysis.
- Hepatic Fat & Cardiovascular Biomarkers: In a 12-month randomized double-blind trial published in The Lancet HIV (Fourman et al., 2019), tesamorelin reduced relative hepatic fat fraction by 37%, resolved steatosis in 35% of treated participants (vs. 4% on placebo), and prevented histological liver fibrosis progression (10.5% vs. 37.5%). Additional trials documented significant reductions in triglycerides (−37 to −50 mg/dL), non-HDL cholesterol, C-reactive protein, and carotid intima-media thickness (cIMT).
- Cognitive & BDNF/GABA Brain Study (Baker et al., JAMA Neurology, 2012): In a 20-week randomized trial of 152 older adults (healthy seniors and adults with mild cognitive impairment), tesamorelin significantly improved executive function and verbal memory while increasing brain levels of N-acetylaspartate (NAA) and myo-inositol/GABA ratios on proton magnetic resonance spectroscopy.
- Where CJC-1295 + Ipamorelin Excels: While CJC-1295 + Ipamorelin produces milder overall visceral fat mobilization than 1–2 mg/day of tesamorelin, its lower cost per cycle, gentler IGF-1 slope (+40%–75%), and direct GHS-R1a activation in sleep-regulating hypothalamic nuclei make it widely studied for Stage 3/4 slow-wave sleep architecture, connective-tissue collagen turnover, and training recovery over 12-to-16-week blocks.
Dosing Protocols, Fasting Rules & 5-On / 2-Off Cycling
A non-negotiable biochemical rule applies to both Tesamorelin and CJC-1295 + Ipamorelin: elevated serum insulin and free fatty acids potently blunt pituitary somatotroph GH release. Administering either secretagogue shortly after a carbohydrate- or fat-containing meal suppresses the resulting GH pulse by 50% to 80%. Both protocols require a strict 90-to-120-minute post-meal fast before injection and waiting at least 30 minutes after injection before eating.
| Protocol Element | Tesamorelin Research Protocol | CJC-1295 (No DAC) + Ipamorelin Protocol |
|---|---|---|
| Daily Dose Range | 1.0 mg to 2.0 mg (1,000–2,000 mcg) once daily (1.4 mg in concentrated Egrifta SV; 1.28 mg in Egrifta WR) | 100–200 mcg Mod GRF(1–29) + 100–200 mcg Ipamorelin once or twice daily |
| Optimal Administration Timing | Pre-bedtime (≥2 hrs after dinner) to amplify the primary nocturnal GH pulse, or fasted AM | Pre-bedtime (≥2 hrs after dinner); optional second pulse fasted upon waking |
| Weekly Schedule | 5 days on / 2 days off (research standard) or 7 days/wk (FDA Phase 3 trial design) | 5 days on / 2 days off to preserve GHS-R1a and GHRH-R receptor sensitivity |
| Cycle Length & Washout | 8 to 16 weeks active cycle, followed by 4-week washout (note: VAT returns if lifestyle/metabolic state is unchanged) | 12 to 16 weeks active cycle, followed by 4-week receptor reset washout |
| Can Tesamorelin Pair With Ipamorelin? | Yes — advanced metabolic protocols often pair 1.0 mg Tesamorelin (GHRH-R) with 100–200 mcg Ipamorelin (GHS-R1a) pre-bed, replacing CJC-1295 with full-length Tesamorelin. Never stack Tesamorelin and CJC-1295 simultaneously, as both compete for the identical GHRH receptor. | |
Frequently Asked Questions
Which is more effective for losing visceral belly fat: Tesamorelin or CJC-1295 + Ipamorelin?
Tesamorelin is significantly better validated and more potent for selective visceral adipose tissue (VAT) reduction. In multiple Phase 3 randomized controlled trials (NEJM, JAMA), tesamorelin reduced CT-measured visceral fat by 15.2% at 26 weeks and 18% to 20% at 52 weeks without depleting subcutaneous fat, whereas CJC-1295 + Ipamorelin produces milder general lipolysis.
Can you stack Tesamorelin and CJC-1295 together?
No, stacking Tesamorelin and CJC-1295 is pharmacologically redundant because both are GHRH analogs that compete for the exact same pituitary GHRH receptor. However, researchers frequently stack Tesamorelin (a GHRH receptor agonist) with Ipamorelin (a ghrelin GHS-R1a agonist) to achieve dual-receptor synergy using full-length GHRH(1–44).
Why do researchers use a 5 days on, 2 days off schedule for growth hormone secretagogues?
Although clinical trials of Egrifta dosed tesamorelin 7 days per week, wellness and research protocols commonly use a 5-days-on, 2-days-off schedule (especially when combining a GHRH analog with Ipamorelin) to prevent GHS-R1a beta-arrestin receptor desensitization, maintain baseline insulin sensitivity, and reduce monthly compound cost by ~28%.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29)?
CJC-1295 without DAC (Modified GRF 1-29) has a ~30-minute half-life that produces a natural, physiologic GH pulse and then clears, preserving pituitary trough periods. CJC-1295 with DAC contains a reactive maleimidopropionic acid linker that binds serum albumin for a 6-to-8-day half-life, creating continuous non-pulsatile GH elevation.
Does Tesamorelin or CJC-1295 + Ipamorelin affect blood sugar or HbA1c?
Because growth hormone is a counter-regulatory hormone to insulin that mobilizes free fatty acids, high-amplitude GH elevation can mildly increase fasting glucose or HbA1c (+0.1% to +0.2% mean shift in Phase 3 tesamorelin trials). Monitoring fasting glucose, fasting insulin, and serum IGF-1 SD scores before and during any secretagogue cycle is standard clinical practice.
What happens to visceral fat after stopping Tesamorelin?
In the 52-week NEJM crossover trial (Falutz et al.), patients who switched from tesamorelin to placebo at Week 26 re-accumulated most of their lost visceral adipose tissue over the following 26 weeks unless underlying insulin resistance and caloric balance were corrected.
Research Disclaimer
All content on this page is provided for informational and educational research purposes only. While Tesamorelin (Egrifta) is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, off-label use and investigational peptides such as CJC-1295 and Ipamorelin are not FDA-approved for anti-aging or body-composition enhancement. Growth hormone secretagogues are contraindicated in active malignancy. Always consult a licensed physician before using any compound.